Objective: To study visceral fat and conventional and exploratory cardiovascular risk factors in patients with AD.
A
ddison's disease (AD), or primary adrenal insufficiency, is a rare disease with an estimated prevalence of 90 to 140 per 1 million inhabitants that is characterized by deficiency of glucocorticoids (GCs), mineralocorticoids, and adrenal androgens (1) . Autoimmune adrenalitis is the most common cause of AD in the developed world. Conventional treatment of AD is replacement therapy with GC combined with a mineralocorticoid aiming to mimic the physiologic circadian rhythm of cortisol production and to ensure adequate daily cortisol exposure (1) .
In the 1960s, studies suggested that only undiagnosed patients and patients living under poor social circumstances were at increased risk of death, whereas for patients receiving good clinical surveillance, the expectation of life should not be shortened (2, 3) . More recent studies, however, have shown a more than twofold increased mortality, which, in some studies is mainly due to cardiovascular disease but also to malignancies, infections, and sudden death (4) (5) (6) .
Patients with secondary adrenal insufficiency who use a daily hydrocortisone (HC) replacement dose $20 mg have an adverse cardiovascular risk profile with increased waist circumference and an adverse lipid profile (7) . Replacement doses of HC are commonly .20 mg/d in published studies of patients with AD (4, 8, 9) . Therefore, consistent with results from patients with secondary adrenal insufficiency, studies of patients with AD have shown increased body mass index (BMI), waist circumference, adverse lipid profile, impaired glucose tolerance, and increased prevalence of hypertension (10) (11) (12) (13) . Several studies have demonstrated an increased prescription rate for drugs to control cardiovascular risk factors (11, 12, 14) .
GC and mineralocorticoid receptors are widely expressed in the cardiovascular and immune system (15) , suggesting that adverse effects other than classical risk factors for cardiovascular disease can be obtained if exposure or activation of the receptors is nonphysiologic. Changes in the diurnal sleep-wake pattern, such as in shift workers, is strongly associated with cardiovascular risk (16) . Thus, GCs may impact the cardiovascular risk profile by changing the circadian rhythm in peripheral tissues (17) .
Because central adiposity is a cardinal feature of excessive cortisol exposure (18) and an important risk factor for cardiovascular disease (19) , we hypothesized that visceral abdominal adipose tissue (VAT) is a sensitive measure of relative GC overexposure in patients with AD. Thus, the primary aim of this cross-sectional case-control study was to study VAT in patients with AD compared with healthy control subjects. Secondary aims were to study the prevalence of the metabolic syndrome (MetS) and biomarkers of endothelial function and cardiovascular risk.
Methods

Study design
This was a cross-sectional, single-center, case-control study conducted at the Centre for Endocrinology and Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden.
Ethical consideration
Ethical approval for the study was obtained from the ethics committee at the University of Gothenburg. Informed consent was obtained from all participants before any elements of the study were performed. The study was conducted according to the latest Declaration of Helsinki.
Subjects
Adult patients from western Sweden, diagnosed with AD at the age of 18 years or older, were invited to participate. In Gothenburg, patients were identified using the Hospital Diagnosis Register. Endocrinologists in four other hospitals in the region were also asked to identify patients for participation. An invitation letter was sent to eligible patients or handed out at regular clinical visits.
Patients with secondary adrenal insufficiency due to hypothalamic-pituitary disease, those receiving ongoing or recent pharmacologic treatment with GCs, and patients with any severe disease that could interfere with successful participation in the study were precluded from being enrolled.
Matched control subjects from the Gothenburg region were recruited from a random population sample obtained from the Swedish Population Registry. Control subjects matched for age and sex were invited by letter and those responding to the invitation, who were also matched with the same smoking habits and BMI as the patients, were enrolled.
Methods
Patients and control subjects were studied on a single occasion. Medical histories and information on current medical conditions and concomitant medications were collected, and a physical examination was performed. Blood pressure was measured with a mercury sphygmomanometer, using a standard cuff with the subject in a sitting position after a rest for at least 5 minutes. The mean of three measurements with a 1-minute interval in between was used. Height was measured to the nearest 1 cm with the subject barefoot. Weight was measured to the nearest 0.1 kg with the subject wearing lightweight indoor clothes. Waist was measured at the umbilical level using a soft tape. MetS was defined according the criteria set by the International Diabetes Federation (20) .
Fasting blood samples were collected in the morning (between 8:00 and 10:00 AM) after an overnight fast and analyzed for levels of glucose, insulin, glycated hemoglobin (HbA1c), lipids, high-sensitivity C-reactive protein (hs-CRP), tissue-type plasminogen activator 1 (PAI-1), adiponectin, serum cortisol, and thyroid-stimulating hormone (TSH). A panel of 92 established and exploratory circulating cardiovascular risk biomarkers were also determined in serum. The patients took their usual HC morning dose at home with a glass of water before the sampling. Urinary free cortisol (UFC) was analyzed from 24-hour urine collections (24h UFC), and urinary creatinine was measured to assess the adequacy of the urine sampling.
The following analyses were performed in a single batch at the end of study in both patients and control subjects: serum total cholesterol, triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were determined by enzymatic methods (Cobas 6000 and 8000; Roche Diagnostics Scandinavia AB) with a within-assay coefficient of variation (CV) of 3%, 4%, 5%, and 4%, respectively. A particle-enhanced immunoturbidometric method (Modular P800; Roche Diagnostics, Mannheim, Germany) was used to measure hs-CRP with a CV of 4% and 3% at serum concentrations of 1 mg/L and 15 mg/L, respectively. Adiponectin was analyzed using an enzyme-linked immunosorbent assay kit (Millepore, Billerica, MA) with a CV of 11% at 2.1 mg/L and 7% at both 11.5 mg/L and 22 mg/L, respectively. Serum cortisol was measured using a competitive electrochemiluminescence immunoassay (Cortisol Elecsys; Roche Diagnostics Scandinavia AB) and 24h UFC was measured via radioimmunoassay (SpectRia Cortisol 125I; Orion Diagnostica, Oy, Finland) with a normal range of 75 to 350 nmol per 24 hours; the CV was 6.8% at 61 nmol/L and 5.5% at 160 nmol/L and 380 nmol/L. TSH was measured using an immunometric methodology (Roche Modular/Cobas; Rotkreuz, Switzerland) with a normal reported range of 0.27 to 4.2 mIU/L and a CV of 5%.
Plasma glucose concentrations were measured using an enzymatic hexokinase method (GLU; Roche/Hitachi; Roche Diagnostics, Mannheim, Germany), serum insulin was measured with an immunometric two-step sandwich method and chemiluminescence technology (Insulin Elecsys; Roche Diagnostics), and HbA1c was calculated using a chromatographic method (Kolon Mono-S; Amersham Pharmacia Biotech, Uppsala, Sweden).
HbA1c percentage was measured by Mono-S and by calculating to International Federation of Clinical Chemistry standardization of HbA1c, as follows: (10.11 3 Mono-S) 2 8.94; HbA1c 4.5% and 4.4% thus are equivalent to 36 mmol/ mol and 35 mmol/mol, respectively (21) . Insulin resistance was calculated according to the homeostasis model of assessment for insulin resistance 1 (HOMA1-IR) from fasting plasma insulin and glucose concentrations (22) .
A panel of 92 cardiovascular biomarkers were analyzed simultaneously in plasma samples from all patients, using the proximity extension assay on the Proseek Multiplex CVD I panel (Olink Bioscience, Uppsala, Sweden). The proximity extension assay generates quantification cycle values and the data are normalized for both intra-and interplate variation and a fixed correction factor is used. The protein analysis is then reported in log2 scale as normalized protein expression units where a high value corresponds to high protein concentration.
Computed tomography (CT; General Electric High-Speed Advantage CT system, version RP2; GE Medical Systems, Milwaukee, WI) was used to estimate body composition. The voltage of the tube was 120 kV and the section thickness was 5 mm. The fourth lumbar vertebra level (L4) was used to determine VAT. Subcutaneous adipose tissue (SAT) was measured at L4 and the midthigh region. The intermuscular adipose tissue (AT) and the cross-sectional muscle area were measured at the midthigh region. The CV for all body compositional measurements was ,1%. The hepatic fat content was determined by the attenuation of the liver in Hounsfield units (HU).
Statistics
All statistical analyses were performed with SPSS (version 22.0; IBM, Somers, NY). Data are presented as mean 6 standard deviation (SD) or median [interquartile range (IQR)]. For comparison between groups, an unpaired t test was used for normally distributed data and the Mann-Whitney U test for nonnormally distributed data. For proportions, Pearson x 2 or Fisher exact tests were used. A two-tailed P value ,0.05 was considered statistically significant.
A multiple regression analysis and a logistic regression analysis were performed to study the influence of cortisol exposure (24h UFC) and HC dose on VAT and MetS, respectively, after adjustment for age, sex, and weight. The cardiovascular risk biomarkers were analyzed with analysis of covariance. Significant biomarkers after correction for multiple testing are presented as fold changes (FCs) with 95% confidence intervals.
Results
Subject characteristics and frequency of MetS
The clinical characteristics of patients and control subjects are shown in Table 1 . The mean 6 SD age was 53 614 years and BMI was 25 64 kg/m 2 . The mean 6 SD duration of AD was 17 612 years. The median (range) daily HC and fludrocortisone doses were 30 mg (10 to 50 mg) and 0.1 mg (0 to 0.2 mg), respectively. Most patients (71%) were using a twice-daily HC regimen.
Serum cortisol, 24h UFC, and the urinary cortisol/ creatinine estimates were higher in patients than in control subjects (P , 0.001 for all variables). Forty-five percent of the patients and 3% of the control subjects had diagnosed hypothyroidism (P , 0.001), but the TSH concentration did not differ between the groups. Thirty-nine patients (51%) had autoimmune polyendocrine syndrome type 2.
Systolic and diastolic blood pressures were similar in patients and control subjects, but more patients than control subjects were using antihypertensive medications (21% vs 5%, respectively; P = 0.004).
Patients with type 1 diabetes mellitus (T1DM) had insulin, and of patients with type 2 diabetes mellitus (T2DM), two used metformin only, two used repaglinide only, one used both metformin and repaglinide, one used combination insulin, and one had a dietary recommendation. The only control subject with T2DM had a dietary recommendation. MetS criteria were fulfilled by 26 patients (34%) and 12 control subjects (16%; P = 0.01). After adjustment for age, weight, and sex, no association was found between the dose of HC or 24h UFC and the presence of the MetS.
After exclusion of participants with T1DM or T2DM and their matching patient or control subject, the use of antihypertensive treatment (P = 0.041) and presence of the MetS (n = 16 patients vs 9 control subjects; P = 0.1) was still more common in patients than in controls.
Body composition by CT
The median (IQR) VAT area did not differ between the patients and control subjects [76 cm 2 (39 to 132 cm 2 ) vs 71 cm 2 (43 to 135 cm 2 ); P = 0.7; Fig. 1 .] There was no difference in VAT area between male patients and their matched control subjects or female patients and their matched control subjects. Also, the abdominal SAT, the thigh intermuscular AT and SAT, and the thigh muscle area (Table 2) did not differ between the groups. The liver attenuation was, however, increased in the patients as compared with the control subjects [median (IQR), 59 HU (57 to 61 HU) vs 57 HU (54 to 61 HU); P = 0.03], suggesting reduced hepatic fat content. After adjustment for age, weight, and sex, there was no association between VAT and the daily dose of HC or the 24h UFC as a measure of total cortisol exposure.
Glucose metabolism A total of 12 patients (16%) had DM (n = 5 T1DM and n = 7 T2DM) and one control subject (1%) had T2DM (P = 0.001). There were no differences between the groups in fasting plasma glucose or fasting insulin levels, and in HOMA index (Table 3) , including all with DM; however, the patients had higher HbA1c (P = 0.007). After excluding all patients with DM and their matching patient or control subject, the fasting plasma glucose was lower in patients [median (IQR), 4.5 mmol/L (4.2 to 4.8 mmol/L)] than control subjects [4.7 mmol/L (4.3 to 5.2 mmol/L); P = 0.014], but HbA1c was comparable in the two groups [median (IQR), 4.4% (4.1% to 4.7%) vs 4.3% (4.1% to 4.5%) for patients and control subjects, respectively; P = 0.10].
Lipids and inflammatory and fibrinolytic markers
More patients than control subjects were using lipidlowering treatment (15% vs 1%; P = 0.003; Table 1 ). Serum TG concentrations were higher (P = 0.03), but HDL-C and LDL-C were lower (P , 0.0005 and P = 0.03, respectively) in patients (Table 3) . TG level was $1.7 mmol/L in 18 patients compared with six control subjects (P = 0.007).
By excluding subjects receiving lipid-lowering therapy (n = 11 patients and one control subject) and their Elevated TG levels and reduced HDL-C persisted when all patients with DM and their matching patient or control subject were excluded from the analysis. Adiponectin and hs-CRP levels, and PAI-1 did not differ between the groups (Table 3) .
Biomarkers for cardiovascular risk
Patients with AD and matched control subjects had nominally significantly different concentrations in 43 of the 92 studied proteins and in 17 proteins, after correction for multiple inference (Fig. 2) . Inflammatory, proinflammatory, and proatherogenic risk biomarkers such as interleukin 6 (IL-6), protein S-100-A12, fractalkine (CX3CL1), resistin (RETN), follistatin, interleukin-1 receptor antagonist, myeloperoxidase, and matrix metalloproteinase-3 were all higher (FC, .1), whereas a vasodilatory factor adrenomedullin was decreased in patients (FC, ,1) .
The orexigenic factors, agouti-related protein and galanin peptides were decreased in patients (FC, ,1) . Moreover, GC responsive proteins were altered, notably osteoprotegerin was reduced and Caspase-8 was increased in patients with AD.
Discussion
In this case-control study of patients with AD matched for age, sex, BMI, and smoking habits, the VAT area was not significantly different between groups, despite increased total cortisol exposure among patients. Despite Abbreviation: TC, total cholesterol. a Statistically significant at P , 0.05. no apparent differences in VAT area, the frequency of MetS was increased in patients with AD. In addition, several biomarkers of cardiovascular disease differed between the patients and control subjects, indicating a more unfavorable cardiovascular risk profile in patients with AD. Marked chronic GC excess, as seen in Cushing syndrome, results in increased abdominal fat mass, glucose intolerance, and hypertension (18) . The increased serumcortisol peak concentration in the morning and the increased 24h UFC in this study indicate an increased exposure to cortisol in the patients than in control subjects. This is supported by reduced levels of GC responsive markers such as osteoprotegerin (odds ratio, 0.87) (23) and increased levels of caspase-8 (odds ratio, 1.56) (24) . This strongly suggests that mean HC doses of 30 mg/d in this as well as in many previous studies on patients with adrenal insufficiency result in a nonphysiologic increased cortisol exposure (4, 9, 10). Fold change with 95% confidence intervals of circulating protein biomarkers in patients with AD compared with matched control subjects. AGRP, agouti-related protein; AM, adrenomedullin; CASP-8, Caspase 8; CX3CL1, fractalkine; EN-RAGE, protein S-100-A12; FS, follistatin; GAL, galanin peptide; IL-1ra, interleukin-1 receptor antagonist; IL-6, interleukin 6; MMP-3, matrix metalloproteinase-3; MMP-12, matrix metalloproteinase-12; MPO, myeloperoxidase; OPG, osteoprotegerin; RETN, resistin; SCF, stem cell factor; TIE2, angiopoietin-1 receptor; U-PAR, urokinase plasminogen activator surface receptor.
In this study of VAT in patients with AD, VAT area was not increased despite higher cortisol exposure. It is possible that VAT is not a sensitive marker of excess cortisol exposure in the setting of GC replacement therapy in patients with adrenal insufficiency, in contrast to what we originally hypothesized. This study, therefore, indicate that it is not only the total exposure over 24 hours but a disturbed diurnal pattern of exposure that may be important for developing excess abdominal fat, such as in Cushing syndrome or even subclinical hypercortisolism, where the diurnal rhythm of cortisol is changed into a more continuous cortisol exposure (25) . Higher GC doses with even higher cortisol exposure could induce increased VAT in patients with AD, but the absence of a more continuous exposure, as seen in patients with Cushing syndrome, may also counteract the gain in VAT.
Increased TG concentration and reduced HDL-C, as shown in this study of patients with AD, are associated with an increased risk for cardiovascular disease. The central obesity is thought to be the main driver of increased very-low-density lipoprotein secretion from the insulin-resistant liver (26) . Although VAT area was not increased in the patients in this study, the higher TG level may be explained by an acute effect of the supraphysiologic cortisol concentrations hours after intake of their morning HC doses, resulting in increased hepatic TG output (27) . Another explanation could be decreased lipoprotein lipase activity and increased catecholamine release during the night, with increased lipolysis and free fatty acid exposure to the liver secondary to the low nighttime cortisol exposure (28) . Both mechanisms are consistent with the finding that TG level was increased yet VAT area was not. The increased liver attenuation suggesting reduced hepatic fat content in patients may support this mechanism of action. However, increasing overnight cortisol exposure using a pump infusion of HC did not change TG concentration, which argues against low nighttime cortisol exposure explaining this finding (29) .
The increased disease burden from cardiovascular disease in patients with AD is probably multifactorial. Both chronic GC treatment and the autoimmune disease per se may affect adaptive mechanisms in atherosclerotic inflammation. Although pharmacologic GC treatment is considered anti-inflammatory, the nonphysiologic GC replacement may influence the immune system differently; however, the autoimmune nature of the disease with increased inflammatory signature may also influence the immune profile in patients with AD. In this study, levels of key proinflammatory, proatherogenic risk biomarkers such as IL-6 (30), protein S-100-A12 (31), CX3CL1, RETN (32), follistatin (33), interleukin-1 receptor antagonist (34) , myeloperoxidase (35) , and matrix metalloproteinase-3 (36) were all significantly increased in the patients compared with matched control subjects. These proteins are suggested to be associated with atherosclerotic processes, including inflammation. Like hs-CRP, IL-6 is a nonspecific marker of inflammation and associated with risk of cardiovascular events (30) . Atherogenic inflammation may evolve due to dysregulation between the innate and adaptive immune systems as well as upregulation of the adaptive immune system. Chronic GC replacement may predispose to this dysregulation. This is supported by our data from the biomarker screening and specifically by the increased RETN and CX3CL1 concentrations in patients, the former originating from leukocytes and the latter expressed by endothelial and vascular smooth muscle cells that may play interactive roles in atherogenesis (32) . The increased IL-6 levels in patients could reflect impaired interaction between the T lymphocytes, T-effector cells and T-regulatory cells, with imbalance between proinflammatory and anti-inflammatory cytokines inducing a state of chronic inflammation.
Furthermore, concentration of adrenomedullin, a protein with vasodilatory action (37) , was decreased in patients with AD. This implies that patients with AD have a higher vascular tone, which has been shown to be GC dose dependent (38) . In addition, two peptides involved in food intake behavior in the central nervous system, the orexigenic agouti-related protein and galanin peptides, were decreased in plasma of patients with AD. These peptides in the CNS induce increased food intake in animal models (39) . Whether their importance in peripheral tissue (i.e., plasma) reflects the CNS effect is not known.
The MetS is strongly associated with an increased risk of T2DM and cardiovascular disease (26) . In a retrospective study of mild cortisol excess in patients with adrenal incidentalomas, the prevalences of T2DM, coronary heart disease, and cardiovascular mortality were increased (40) . Thus, the changes observed in lipids, glucose metabolism, and the increased prevalence of the MetS in the patients with AD could partially explain the increased cardiovascular mortality we and others have observed (4, 5) .
We consider the major strength of this study to be a relative large group of patients with this rare disease, and a successful matching between patients and control subjects for age, sex, BMI, and smoking status. The patients with AD in our study are probably representative of patients with AD in Scandinavia (13), but we acknowledge that the control group, although randomly selected from the population, may be healthier than the general population, owing to a response bias. Other important limitations are that lifestyle, dietary habits, alcohol consumption, exercise and socioeconomic status were not controlled for in the matching process.
In conclusion, patients with AD in this study who received a conventional GC replacement dose and regimen had a higher prevalence of MetS but not an increased VAT area in comparison with closely matched control subjects. Additionally, these patients exhibited an adverse cardiovascular biomarker profile related to inflammation and endothelial function. Our findings may be explained by the nonphysiologic HC replacement-dose regimen that, in turn, may translate into excess mortality from cardiovascular diseases.
